Early and high Influenza A circulation alongside reduced Respiratory Syncytial Virus prevalence during autumn 2025 in paediatric patients attending emergency department Velia Chiara Di Maio, Rossana Scutari, Stefania Ranno, Luana Coltella, Venere Cortazzo, Luna Colagrossi, Anna Chiara Vittucci, Livia Antilici, Giulia Linardos, Alessandra Salvatori, Leonarda Gentile, Manuela Onori, Barbara Lucignano, Gianluca Vrenna, Mara Pisani, Sebastian Cristaldi, Massimiliano Raponi, Cristina Russo, Paola Bernaschi, Alberto Villani, Carlo Federico Perno Italian Journal of Pediatrics, 2026 The recent implementation of preventive strategies against Respiratory Syncytial Virus (RSV) in infants has raised questions about potential changes in RSV seasonality and the circulation of other respiratory viruses. This study aimed to compare respiratory virus activity among paediatric patients presenting to the Bambino Gesù Children's Hospital (Rome, Italy), with respiratory symptoms and available BioFire Respiratory Panel 2.1 plus results during September-December 2024 (N = 670) and 2025 (N = 905). RSV detection decreased significantly in December 2025 compared with the same period in 2024 (6.3% vs 29.4%, risk ratio [RR]: 0.21, 95% confidence interval [CI] 0.16-0.28; p < 0.001). By contrast, influenza A viruses had an earlier onset in 2025 and emerged as the dominant pathogen compared with 2024 (21.0%, in 2025 vs 4.5%, in 2024; RR: 4.69, 95% CI 3.23-6.80; p < 0.001). Unlike September-December 2024, parainfluenza viruses (PIVs) 3 and 4 circulated in 2025 (0.4% vs 3.5% for PIV 3; 0.0% vs 3.6% for PIV-4; p < 0.001 for both), mainly observed in infants (median age 0.7 years; interquartile range: 0.2-1.2; mean±standard deviation: 0.9 ± 0.8). Circulation of adenovirus (11.5%, vs 6.1%; p < 0.001) and human coronavirus HKU1 (3.6%, vs 0.1%; p < 0.001) also increased in 2025 compared with 2024. The observed epidemiological shifts suggest potential effects associated with the introduction of RSV prophylaxis in Italy and highlight the importance of continued paediatric surveillance in monitoring evolving viral patterns and guiding public health decisions.
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: A refined analysis through next-generation sequencing Daniele Armenia, Claudia Alteri, Valeria Micheli, Tiziano Allice, Celestino Bonura, Bianca Bruzzone, Isabella Bon, Romina Corsini, Alessandro Zerbini, Loriana Morelli, Francesco Cerutti, Giovanni Giammanco, Nadia Randazzo, Alessia Bertoldi, Federica Novazzi, Gabriele Ibba, Ada Bertoli, Antonia Bezenchek, Francesca Ceccherini-Silberstein, Maurizio Zazzi, Maria Mercedes Santoro Journal of Antimicrobial Chemotherapy, 2026 Background Monitoring HIV-1 subtype circulation and transmitted drug resistance (TDR) remains a key priority, particularly since the rollout of high-sensitivity next-generation sequencing (NGS). Methods Routine plasma HIV-1 RNA NGS genotyping data were collected from newly diagnosed individuals in Italy over 2022–24. HIV-1 TDR and genotypic susceptibility were evaluated through HIVdb with NGS set at 10% and 20%. Subtype and transmission clusters (TC) were determined through the maximum likelihood phylogeny based on the GTR + F + R9 model. Results Seven hundred and forty-two individuals were included, 51.9% harbouring non-B strains [CRF02_AG (18.1%); CRF BF (6.1%); A1/A3/A6 (7.1%); others (20.5%)]. TDR prevalence to any class was 11.7% at Sanger-like NGS-setting (&gt;20%), slightly increased (15.0%) at 10% NGS-setting, and significantly varied across subtypes, with the highest prevalence observed in B subtype. Most antiretrovirals showed full genotypic activity in nearly 99% of individuals, except for efavirenz and rilpivirine (proportion of individuals with full activity &lt;92%). A total of 57 TC were detected: 40 pairs, 17 clusters (&gt;2 sequences). Thirteen TC (22.8%, 8 pairs, 5 clusters) involved individuals harbouring TDR. TDR was detected as minority mutations in five TC. Conclusions A high proportion of HIV-1 non-B subtypes circulate in Italy. TDR prevalence is around 12% using NGS at Sanger-like threshold and moderately increases to 15% when NGS is set at 10%. However, the impact of the detected TDR on the susceptibility to currently used antiretrovirals in clinical practice is negligible.
Diagnostic Concordance of Two- and Three-Gene SARS-CoV-2 Molecular Assays in Cameroon: Implications for Efficient Pandemic Response in Low- and Middle-Income Countries Aurelie Minelle Kengni Ngueko, Sandrine Claire Djupsa Ndjeyep, Ezechiel Ngoufack Jagni Semengue, Alex Durand Nka, Collins Ambe Chenwi, Aude Christelle Ka'e, Yagai Bouba, Jeremiah Efakika Gabisa, Evariste Molimbou, Naomi‐Karell Etame, Tatiana Anim‐Keng Tekoh, Rachel Audrey Nayang Mundo, Pamela Patricia Tueguem, Vincent Kamael Mekel, Hugues Mba, Désiré Takou, Grace Angong Beloumou, Michel Carlos Tommo Tchouaket, Larissa Gaelle Moko Fotso, Derrick Tambe Ayuk, Christian Ngongang Ouankou, Claudia Alteri, Luna Colagrossi, Yap Boum, Halle Gregory Eddy Ekane, Francesca Ceccherini‐Silberstein, Vittorio Colizzi, Nicaise Ndembi, Alfred K. Njamnshi, Alexis Ndjolo, Carlo‐Federico Perno, Maria‐Mercedes Santoro, Joseph Fokam Journal of Clinical Laboratory Analysis, 2026 Background The scale‐up of molecular assays for diagnosing emerging pathogens has increased in low‐and‐middle‐income countries (LMICs) since the advent of COVID‐19. We herein evaluated the diagnostic concordance of three different assays for SARS‐CoV‐2 in Cameroon. Methods A laboratory‐based comparative study was performed on nasopharyngeal samples collected between March‐2020 to March‐2023 from the biobank of Chantal Biya International Reference Centre (CIRCB), Yaoundé‐Cameroon. Samples were analyzed using DaAn Gene (N/ORF1ab‐genes), ThermoFisher (N/ORF1ab/S‐genes), and GeneXpert (N2/E‐genes). Validated cycle thresholds (CT) for positivity were CT < 37 for DaAn Gene/ThermoFisher and CT < 40 for GeneXpert. Cohen's Kappa coefficient evaluated diagnostic concordance with DaAn Gene as reference. Results We analysed 249 samples (55.8% males, median‐age [IQR], 36 [27–50] years including 21.3% symptomatic participants). Overall positivity rates (median [IQR]) were 55.0% (CT: 30.6 [23.1–35.5]); 53.4% (CT: 26.6 [21.2–30.9]); 22.1% (CT: 32.7 [26.9–36.1]) for GeneXpert, DaAn Gene and ThermoFisher respectively. GeneXpert showed stronger concordance with DaAn Gene (83.1%; k = 0.66, 95% CI: 0.57–0.75) than ThermoFisher (67.9%; k = 0.38, 95% CI: 0.29–0.47). At validated thresholds, GeneXpert showed higher positive agreement with DaAn Gene (85.0%, 113/133) as compared to ThermoFisher (41.3%, 55/133), while maintaining comparable negative agreement (81.0% [GeneXpert] and 98.3% [ThermoFisher]). At low CTs (< 20) however, positive agreement with DaAn Gene was high for GeneXpert (100%, 15/15) and ThermoFisher (93.3%, 14/15). Conclusion GeneXpert exhibits superiority over ThermoFisher in detecting cases of COVID‐19. As expected, agreement between two‐ and three‐genes assays at CT < 20 was excellent, suggesting interoperability of these platforms during outbreaks for high viral loads cases. However, two‐genes assays may be decisive to guide decision‐making for effective public health response while facing intermediate to low‐level viral loads in LMICs.
A new epidemic wave of Bordetella pertussis in paediatric population: impact and role of co-infections in pertussis disease Rossana Scutari, Giulia Linardos, Stefania Ranno, Mara Pisani, Anna Chiara Vittucci, Luana Coltella, Luna Colagrossi, Velia Chiara Di Maio, Annamaria Sisto, Livia Mancinelli, Simona Landi, Sebastian Cristaldi, Massimiliano Raponi, Paola Bernaschi, Alberto Villani, Cristina Russo, Carlo Federico Perno Italian Journal of Pediatrics, 2025 Background In recent months, Bordetella pertussis has reappeared after maintaining a low rate for many years. Although pertussis is usually characterized by a favorable course, several factors can contribute to the severity of the disease, such as mixed respiratory infections. In this study, we evaluate B.pertussis cases observed in the pediatric population followed at the Bambino Gesù Children's Hospital and analyzed the potential impact of co-infections in relation to disease severity. Methods From January to May 2024, a total of 1,151 children and adolescents (both inpatients and outpatients) were screened for the presence of respiratory pathogens, including B.pertussis, with clinically relevant respiratory symptoms. Results Among the 1,151 patients screened, 66 tested positive for B.pertussis. Fourteen patients had respiratory failure, and six of them required intensive care unit (ICU) admission, while 52 had mild infection. 23.3% of patients had B.pertussis alone, while 76.7% had co-infections (including 5 patients admitted to the ICU). A higher co-infection rate was observed in patients with respiratory failure than in those without failure (92.9% vs. 69.0%, p-value:0.041). Rhinovirus, Metapneumovirus and Parainfluenza-virus were the most prevalent in our pediatric population. Co-infections of human bocavirus with B.pertussis were observed exclusively in patients with respiratory failure. Conclusions Our results highlighted an increase in B.pertussis cases from January to May 2024, reaching a peak of cases in the month of May. This study shows a high rate of B.pertussis co-infection, and a trend toward association between B.pertussis and specific viruses, that might play a role in increasing disease severity.
Clinical manifestations and severity of COVID-19 caused by Omicron among paediatric patients aged 0–17 years in Italy Rossana Scutari, Valeria Fox, Jennifer L. Nguyen, Luna Colagrossi, Andrea Smarrazzo, Anna Chiara Vittucci, Laura Cursi, Martina Mastropaolo, Lorena Forquè Rodriguez, Carmen D’amore, Luciano Pacelli, Mustapha M. Mustapha, Claudia Alteri, Jingyan Yang, Antonella De Santis, Romina Quercia, Alessandra Pagliaro, Annarita Granaglia, Vanessa Fini, Srinivas R. Valluri, Cristina Russo, Catia Marques, John M. McLaughlin, Laura Lancella, Marta Luisa Ciofi degli Atti, Andrea Campana, Massimiliano Raponi, Alberto Villani, Carlo Federico Perno Scientific Reports, 2025 SARS-CoV-2 Omicron variant evolved into multiple sub-lineages, some showing increased transmissibility and immune evasion. Despite decreased risk of severe disease, paediatric hospitalization rose. However, factors influencing clinical outcomes remain unclear. A total of 458 whole-genome Omicron sequences from patients 0-17 years, diagnosed with SARS-CoV-2 at Bambino Gesù Children's Hospital (January-December 2023) were analysed. Clinical features, disease severity and circulating variants were assessed. Phylogenetic analysis was performed, and logistic regression identified factors associated with hospitalization. Among patients, 249 (54.4%) were male, with median age 0.6 years. Comorbidities were present in 105 (22.9%) patients, mainly immunocompromised (21.0%). Infections were predominantly from XBB (75.0%), JN.1 (12.4%), BA.5 (7.4%) and BA.2 (5.2%) clades. Upper respiratory infections predominated (73.8%), followed by asymptomatic (17.2%) and lower respiratory infections (4.6%), with nine patients having ≥ 1 co-infection. Comorbidities and lower respiratory infections were positively associated with hospitalization, while upper respiratory infections showed a negative association. Given the recent shift to RGN integrin-binding motif in Omicron sub-lineages, leading to altered pathogenesis, its presence was evaluated, revealing a predominance of RGN (N = 378, 84.6%). In conclusion, COVID-19 severity in paediatric patients was primarily driven by comorbidities and co-infections, while milder cases in healthy children may be associated with RGN integrin-binding motif.
Viral dynamics and factors associated with duration of COVID-19 positivity: evidence from the first-three epidemiological waves in Cameroon Joseph Fokam, Aurelie Minelle Kengni Ngueko, Alex Durand Nka, Collins Ambe Chenwi, Ezechiel Ngoufack Jagni Semengue, Yagai Bouba, Désiré Takou, Nadine Fainguem, Michel Carlos Tommo Tchouaket, Aude Christelle Ka’e, Grace Angong Beloumou, Sandrine Claire Djupsa Ndjeyep, Willy Leroi Togna Pabo, Davy-Hyacinthe Gouissi Anguechia, Naomi-Karell Etame, Evariste Molimbou, Rachel Audrey Nayang Mundo, Aissatou Abba, Samuel Martin Sosso, John Otshudiema Otokoye, Christian Ngongang Ouankou, Claudia Alteri, Luna Colagrossi, Maria-Mercedes Santoro, Francesca Ceccherini-Silberstein, Yap Boum, Edie Gregory Halle Ekane, Alfred K. Njamnshi, Vittorio Colizzi, Nicaise Ndembi, Alexis Ndjolo, Carlo-Federico Perno BMC Infectious Diseases, 2025 BACKGROUND: Coronavirus 2019 (COVID-19) disease progression evidence and viral clearance time remain limited in tropical settings. Understanding this is crucial for public health control measures at community-level. We evaluated the viral dynamics of SARS-CoV-2 infection and factors associated with positivity duration in COVID-19 cases in Cameroon. MATERIAL AND METHODS: We conducted a retrospective cohort-study of SARS-CoV-2 positive cases from the first to third wave (March 2020-October 2021) in Yaounde-Cameroon. RT-PCR was carried out on the participants using nasopharyngeal swabs after every 7 days. SARS-CoV-2 positivity duration was evaluated from the first to last positive PCR-test before a negative result. Epi-info V.7.0 was used for data analyses with p < 0.05 considered statistically significant. RESULTS: A total of 282 participants were enrolled. The mean age was 41 ± 14 years, with male predominant (62.1%). We had 15.6% symptomatic participants of which 59% had cough. The overall median positivity duration was 15[IQR: 9-23] days with 15[IQR: 13-22] in the first, 17[IQR: 12-26] in the second and 9[IQR: 6-12] in the third wave (p < 0.0001). Positivity duration was significantly higher in males (16 versus 14 days, p = 0.03) those aged [35-45] years (16 days) followed by those ≥ 46 years(15 days); p = 0.008). Positivity duration was not affected by presence or absence of symptoms (p = 0.80). No significant correlation was found with viral load (r = 0.03; p = 0.61). Considering baseline (24.7 ± 7.2Ct) and last viral load (29.3 ± 5.9 Ct), the ΔCt (4.6 ± 1.3) and positivity duration (15 days) revealed a kinetic in viral decay of 0.3 ± 0.087 Ct/day. CONCLUSIONS: A median positivity duration of 15 days is in accordance with viral clearance around 2 weeks for optimal confinement at community-level. Men and/or the elderly stand at higher risk of prolonged infection. Given the viral decay (0.3 Ct daily), we suggest personalized confinement periods. The variability of positivity duration according to waves could be function of strains which could be a factor influencing positivity duration.
Whole-Genome Sequencing of Adenovirus Genotypes and Clinical Implications in Pediatric Patients Lorena Forqué, Valeria Fox, Rossana Scutari, Martina Mastropaolo, Pietro Merli, Velia Chiara Di Maio, Vanessa Fini, Giulia Linardos, Luana Coltella, Stefania Ranno, Cristina Russo, Alberto Villani, Carlo Federico Perno, Luna Colagrossi Viruses, 2025 Human adenoviruses (HAdV) comprise more than 100 genotypes with species-specific differences in tropism and immune response and can cause severe infections in immunocompromised patients. This study aimed to characterise the HAdV species involved in pediatric infections to assess their clinical impact and guide future therapeutic strategies based on AdV-specific T-cell responses. Between January and October 2024, 595 pediatric HAdV diagnoses were made at the Bambino Gesù Children’s Hospital (Rome), and whole-genome sequencing was performed on 60 samples. Most patients (91.7%) were hospitalised, including both immunocompetent (75%) and immunocompromised (25%) children. Gastrointestinal and respiratory symptoms were more common in immunocompetent patients, whereas immunocompromised patients experienced longer hospitalisations and persistent viral infections. Species F (F41) was most prevalent (63.3%), especially among immunocompetent patients, while species C and A predominated in immunocompromised children, with species A associated with severe disease. Viral loads were significantly higher for species F than for species A and C, independent of immune status. Co-infections were frequent (63.3%), with species C particularly linked to them. In conclusion, HAdV distribution differed by immune status, with species F predominating in immunocompetent children and species C and A more common in immunocompromised patients. Whole-genome sequencing may enhance surveillance, enable earlier diagnosis, and support the development of genotype-specific immunotherapies.
Viral Burden of Respiratory Syncytial Virus and Viral Coinfections as Factors Regulating Paediatric Disease Severity Velia Chiara Di Maio, Rossana Scutari, Martina Mastropaolo, Luna Colagrossi, Giulia Linardos, Luana Coltella, Stefania Ranno, Eugenia Galeno, Mara Pisani, Anna Chiara Vittucci, Sebastian Cristaldi, Massimiliano Raponi, Alberto Villani, Cristina Russo, Carlo Federico Perno Viruses, 2025 Background: Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infections (ARIs) in children. However, the clinical impact of RSV co-infection with other respiratory viruses remains unclear. This study investigates the frequency and clinical outcomes of RSV infections in a large paediatric cohort. Methods: Paediatric patients with RSV-positive respiratory samples admitted to Bambino Gesù Children’s Hospital between January 2022 and April 2024 were analysed. Results: Within 17,259 respiratory samples from 9877 paediatric patients, 952 (9.6%) were RSV-positive. Among these, 637 patients with ARI were included. RSV affected the lower respiratory tract in 549 cases (86.2%) and the upper tract in 88 (13.8%) cases. RSV mono-infection was found in 286 (44.9%) patients, while 351 (55.1%) patients had co-infections. Mono-infections showed lower cycle-threshold (CT) than co-infections in both upper and lower tract (p-value:0.002 and 0.037, respectively). Pneumonia was associated with RSV co-infection (N = 48, 15.4%), whereas bronchiolitis was mostly seen in mono-infection (N = 196, 78.1%, p-value:0.002). Regression analysis showed an association between pneumonia and co-infection (AOR: 1.97 [1.06–3.64], p-value = 0.031), higher CT (AOR [95% CI]: 1.07 [1.02–1.11], p-value = 0.006) and older age (AOR [95% CI]: 1.48 [1.31–1.68], p-value < 0.001), whereas bronchiolitis was associated with mono-infection, younger age and lower CT. Conclusions: This study highlights the role of RSV in paediatric disease and emphasises the importance of early diagnosis, personalised treatment and preventive strategies to improve outcomes and reduce the burden of disease.
Assessing the utilization of HIV genotype resistance testing: Insight from Italian Infectious Diseases Units Andrea De Vito, Antonia Bezenchek, Rossana Scutari, Luna Colagrossi, Giacomo Valenti, Maria Concetta Bellocchi, Luca Pipitò, Sergio Ferrara, Sergio Malandrin, Monica Tallarita, Alessandro Cozzi-Lepri, Francesca Ceccherini-Silberstein, Sergio Lo Caputo, Stefano Rusconi Journal of Global Antimicrobial Resistance, 2025 • Most (93.3%) centres perform GRT, with significant variability in testing methodology and lab location. • Only 24.5% of centres perform GRT on HIV-DNA before ART changes, highlighting potential areas for improvement. • Larger centres are more likely to have in-house GRT capabilities than smaller ones (91.7% vs. 15.4%). • Most centres receive GRT results within 1 month; however, 23.4% face delays exceeding this time frame. • Study underscores the perceived necessity of GRT in clinical management of treatment-naïve PLWH by 91.5% of respondents. We aimed to assess the utilization of genotype resistance testing (GRT) by Infectious Diseases Units across Italy. A cross-sectional study was conducted involving a questionnaire distributed to the Infectious Diseases Unit in Italy. A web-based survey using Google Forms software was utilized and spread via email or cellphone. Responses were obtained from 101 Infectious Diseases Units. Among these centres, only seven (6.9%) reported not performing GRT at any time. Of the 94 centres performing GRT, 52 (55.3%) sent blood samples to external laboratories. Notably, only 6/35 (17.1%) small centres had internal laboratories, compared to 14/35 (40.0%) medium centres and 22/24 (91.7%) large centres ( P < 0.001). Most centres requested GRT for treatment-naïve individuals and all cases of virological failure. Only 24 (25.5%) requested GRT of HIVDNA before treatment changes. Regarding virological failure, most centres (38, 40.4%) requested GRT when HIV-RNA levels exceeded 200 copies/mL, while 26 (27.7%) requested it at levels exceeding 50 copies/mL. Additionally, 18 (19.1%) and 12 (12.8%) centres requested GRT at thresholds of 500 copies/mL and 1000 copies/mL, respectively. Regarding the specific GRT test used, 34 (36.2%) were unsure, while 16 (17.0%) reported using both next-generation sequencing and Sanger methods. Furthermore, 30 (31.9%) and 14 (14.9%) centres exclusively used next-generation sequencing and Sanger, respectively. Most centres reported receiving GRT results within 1 month ( n = 72, 76.6%), while 22 (23.4%) centres obtained results within 2 weeks. However, 22 (23.4%) centres typically experienced more than 1-month delays. Finally, most participants (86, 91.5%) regarded GRT as a crucial routine test for the treatment of naïve people living with HIV. This study demonstrates that most Infectious Diseases Units in Italy continue to consider GRT an essential test for newly diagnosed people living with HIV in clinical practice. However, the utilization of GRT on HIV-DNA remains limited. Further efforts are required to decrease turnaround time in centres experiencing prolonged delays in obtaining results.
Parvovirus B19 Rebound Stefania Ranno, Cristina Russo, Luna Colagrossi, Valeria Fox, Velia Chiara Di Maio, Giulia Linardos, Leonarda Gentile, Rosaria Marotta, Sebastian Cristaldi, Andrea Campana, Mara Pisani, Leonardo Caforio, Alberto Villani, Carlo Federico Perno, Luana Coltella Journal of Medical Virology, 2025 Human parvovirus B19 (B19V) is responsible for a wide clinical spectrum ranging from asymptomatic infection, through mild disease, up to life‐threatening one. Outbreaks are registered every 3–4 years, and a recent international alert for a new outbreak has been released. The experience of B19 virus circulation in a 600‐bed tertiary care pediatric hospital in Rome from 2018 to 2024 is reported here. This retrospective study involved a total of 9695 blood samples (about 8500 patients), 11 amniotic fluids (11 pregnant women), and 10 827 sera (about 9500 patients), processed in the Virology Unit of Bambino Gesù Children's Hospital in Rome for B19V direct and indirect detection. In our population, the annual positivity rate for B19V DNA ranged from 0.8% in 2023 to 9.8% in 2018 and 32.8% in 2024; the same trend resulted from the analysis of the immunoglobulins M and G anti‐B19V. Focusing on the last year, 314 patients resulted positive for B19V DNA detection: 204/314 (65%) had a primary infection, 150/204 (73.5%) were hospitalized, and 17/150 (11.3%) needed Intensive Care Unit (ICU) for cardiovascular, central nervous, and gastrointestinal pathologies. Two patients died from myocarditis. Among patients with the most severe clinical picture, over half had no concurring disease, and one patient died. Four amniotic fluids were positive for pregnant women who came to our observation. B19V typing of a subset of samples revealed the presence of only subtype 1A and a low intragenotypic diversity between strains from severe and mild disease. In conclusion, in 2024, a significant increase in B19V circulation was observed with profound effects on clinical outcome and consequent hospitalisation, either in patients with comorbidities or those without. This widespread circulation of the virus also had an impact on infections in pregnancy, with the known severe consequences for unborn children.
Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in vulnerable groups – The CONVERS project, report from a pediatric tertiary hospital Nicola Cotugno, Marco Sanna, Donato Amodio, Elena Morrocchi, Chiara Pighi, Chiara Medri, Giuseppe Rubens Pascucci, Veronica Santilli, Emma Concetta Manno, Paola Zangari, Chiara Rossetti, Nicole Colantoni, Giulio Olivieri, Elena Emili, Alessia Neri, Arianna Rotili, Paolo Rossi, Ofer Levy, Lorenza Putignani, Paolo Palma, Lorenza Romani, Andrea Finocchi, Caterina Cancrini, Viviana Moschese, Mayla Sgrulletti, Laura Lancella, Stefania Bernardi, Maia De Luca, Carmela Giancotta, Luna Colagrossi, Francesco Bonfante, Elisa Profeti, Enrica Franzese, Antonino Amodeo, Carlo Federico Perno, Marta Ciofi Degli Atti, Carlo Plebani, Carlo Giaquinto, Diletta Valentini, Alberto Villani, Paola De Angelis, Francesca Rea, Renato Tambucci, Beatrice Rivalta, Lucia Pacillo, Gioacchino Andrea Rotulo Vaccine, 2025
Whooping Cough Cases Increase in Central Italy after COVID-19 Pandemic G. Linardos, L. Coltella, S. Ranno, V. D. di Maio, L. Colagrossi, E. Pandolfi, M. B. Chiarini Testa, L. Genuini, Francesca Stoppa, Matteo Di Nardo, Annalisa Grandin, R. Cutrera, C. Cecchetti, Alberto Villani, M. Raponi, Paola Bernaschi, Cristina Russo, C. F. Perno, R. Scutari Antibiotics, 2024
SARS-CoV-2 genomic surveillance and reliability of PCR single point mutation assay (SNPsig® SARS-CoV-2 EscapePLEX CE) for the rapid detection of variants of concern in Cameroon J. Fokam, Davy Hyacinthe Gouissi Anguechia, D. Takou, Ezechiel Ngoufack Jagni Semengue, C. Chenwi, G. Beloumou, S. Djupsa, A. Nka, W. Pabo, Aissatou Abba, A. Ka’e, A. Kengni, Naomi-Karell Etame, Larissa Gaelle Moko, Evariste Molimbou, Rachel Audrey Nayang Mundo, Michel C T Tommo, N. Fainguem, Lionele Mba Fotsing, L. Colagrossi, C. Alteri, Dorine Ngono, J. Otshudiema, Clement Ndongmo, Yap Boum, Georges Mballa Etoundi, Edie G.E. Halle, Emmanuel Eben-Moussi, C. Montesano, A. Marcelin, V. Colizzi, Carlo-Federico Perno, A. Ndjolo, Nicaise Ndembi Heliyon, 2024
High concordance in SARS-CoV-2 detection between automated (Abbott m2000) and manual (DaAn gene) RT-PCR systems: The EDCTP PERFECT-Study in Cameroon N. Fainguem, J. Fokam, Ezechiel Ngoufack Jagni Semengue, Alex Durand Nka, D. Takou, Joshua Ageboh Nkembi-leke, C. Alteri, L. Colagrossi, Roméo Bouba Yagai, Collins Ambe Chenwi, Michel Carlos Tchouaket Tommo, Grâce Angong Beloumou, A. Ka’e, Sandrine Claire Ndjeyep Djupsa, Aissatou Abba, Laeticia Grace Heunko Yatchou, Krystel Nnomo Zam, R. Kamgaing, S. Sosso, Lucien Mama, N. Ndembi, V. Colizzi, C. Perno, G. Cappelli, A. Ndjolo Journal of Public Health in Africa, 2022
Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections S. Terreri, E. Piano Mortari, M. Vinci, C. Russo, C. Alteri, Christian Albano, F. Colavita, Giulia Gramigna, C. Agrati, G. Linardos, L. Coltella, L. Colagrossi, Gloria Deriu, M. L. Ciofi Degli Atti, C. Rizzo, M. Scarsella, R. Brugaletta, V. Camisa, A. Santoro, G. Roscilli, Emiliano Pavoni, Alessia Muzi, N. Magnavita, R. Scutari, A. Villani, M. Raponi, F. Locatelli, C. Perno, S. Zaffina, R. Carsetti Cell Host and Microbe, 2022
Back to the future (of common respiratory viruses) G. Mattana, Sami Albitar-Nehme, V. Cento, L. Colagrossi, L. Piccioni, M. Raponi, U. Raucci, A. Vittucci, A. Reale, A. Villani, Paola Bernaschi, C. Perno Journal of Global Antimicrobial Resistance, 2022
BNT162B2 mRNA COVID-19 Vaccine in Heart and Lung Transplanted Young Adults: Is an Alternative SARS-CoV-2 Immune Response Surveillance Needed? Nicola Cotugno, Chiara Pighi, Elena Morrocchi, Alessandra Ruggiero, Donato Amodio, Chiara Medri, Luna Colagrossi, Cristina Russo, Silvia Di Cesare, Veronica Santilli, Emma Concetta Manno, Paola Zangari, Carmela Giancotta, Stefania Bernardi, Luciana Nicolosi, Marta Ciofi Degli Atti, Massimiliano Raponi, Salvatore Zaffina, Sara Alfieri, Richard Kirk, Carlo Federico Perno, Paolo Rossi, Antonio Amodeo, Paolo Palma Transplantation, 2022
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study Luna Colagrossi, Maria Antonello, Silvia Renica, Marco Merli, Elisa Matarazzo, Giovanna Travi, Marta Vecchi, Jacopo Colombo, Antonio Muscatello, Giacomo Grasselli, Silvia Nerini Molteni, Vittorio Scaravilli, Emanuele Cattaneo, Diana Fanti, Chiara Vismara, Alessandra Bandera, Andrea Gori, Massimo Puoti, Valeria Cento, Claudia Alteri, Carlo Federico Perno BMC Infectious Diseases, 2021
Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies Donato Amodio, Alessandra Ruggiero, Mayla Sgrulletti, Chiara Pighi, Nicola Cotugno, Chiara Medri, Elena Morrocchi, Luna Colagrossi, Cristina Russo, Salvatore Zaffina, Gigliola Di Matteo, Cristina Cifaldi, Silvia Di Cesare, Beatrice Rivalta, Lucia Pacillo, Veronica Santilli, Carmela Giancotta, Emma Concetta Manno, Marta Ciofi Degli Atti, Massimiliano Raponi, Paolo Rossi, Andrea Finocchi, Caterina Cancrini, Carlo Federico Perno, Viviana Moschese, Paolo Palma Frontiers in Immunology, 2021
Highly specific memory b cells generation after the 2nd dose of bnt162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal iga Eva Piano Mortari, Cristina Russo, Maria Rosaria Vinci, Sara Terreri, Ane Fernandez Salinas, Livia Piccioni, Claudia Alteri, Luna Colagrossi, Luana Coltella, Stefania Ranno, Giulia Linardos, Marilena Agosta, Christian Albano, Chiara Agrati, Concetta Castilletti, Silvia Meschi, Paolo Romania, Giuseppe Roscilli, Emiliano Pavoni, Vincenzo Camisa, Annapaola Santoro, Rita Brugaletta, Nicola Magnavita, Alessandra Ruggiero, Nicola Cotugno, Donato Amodio, Marta Luisa Ciofi Degli Atti, Daniela Giorgio, Nicoletta Russo, Guglielmo Salvatori, Tiziana Corsetti, Franco Locatelli, Carlo Federico Perno, Salvatore Zaffina, Rita Carsetti Cells, 2021
Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers Salvatore Zaffina, Claudia Alteri, Alessandra Ruggiero, Nicola Cotugno, Maria Rosaria Vinci, Vincenzo Camisa, Anna Paola Santoro, Rita Brugaletta, Gloria Deriu, Eva Piano Mortari, Ane Fernandez Salinas, Cristina Russo, Stefania Ranno, Luana Coltella, Luna Colagrossi, Ottavia Porzio, Andrea Onetti Muda, Massimiliano Raponi, Marta Ciofi degli Atti, Caterina Rizzo, Alberto Villani, Paolo Rossi, Paolo Palma, Rita Carsetti, Carlo Federico Perno Journal of Virus Eradication, 2021
Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality Claudia Alteri, Valeria Cento, Marta Vecchi, Luna Colagrossi, Diana Fanti, Chiara Vismara, Massimo Puoti, Carlo Federico Perno, Claudia Alteri, Maria Antonello, Chiara Baiguera, Alessandra Bielli, Maurizio Bottiroli, Paolo Brioschi, Daniela Campisi, Stefania Carta, Giorgia Casalicchio, Valeria Cento, Arturo Chieregato, Luna Colagrossi, Valentino Costabile, Jacopo Colombo, Federica Di Ruscio, Oscar Massimiliano Epis, Diana Fanti, Roberto Fumagalli, Thomas Langer, Elisa Matarazzo, Marco Merli, Alice Nava, Silvia Nerini Molteni, Carlo Federico Perno, Massimo Puoti, Silvia Renica, Livia Tartaglione, Nicola Ughi, Chiara Vismara, and Clinical Infectious Diseases, 2021
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets Luna Colagrossi, Romina Salpini, Rossana Scutari, Luca Carioti, Arianna Battisti, Lorenzo Piermatteo, Ada Bertoli, Lavinia Fabeni, Carmine Minichini, Pascale Trimoulet, Hervé Fleury, Elena Nebuloso, Maria De Cristofaro, Giuseppina Cappiello, Alberto Spanò, Vincenzo Malagnino, Terenzio Mari, Angelo Barlattani, Nerio Iapadre, Miriam Lichtner, Claudio Mastroianni, Ilaria Lenci, Caterina Pasquazzi, Giuseppe De Sanctis, Alfonso Galeota Lanza, Maria Stanzione, Gianfranca Stornaiuolo, Massimo Marignani, Loredana Sarmati, Massimo Andreoni, Mario Angelico, Francesca Ceccherini-Silberstein, Carlo-Federico Perno, Nicola Coppola, Valentina Svicher Viruses, 2018
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe on behalf of the HEPVIR working group of the European Society for translational antiviral research (ESAR), Luna Colagrossi, Lucas E. Hermans, Romina Salpini, Domenico Di Carlo, Suzan D. Pas, Marta Alvarez, Ziv Ben-Ari, Greet Boland, Bianca Bruzzone, Nicola Coppola, Carole Seguin-Devaux, Tomasz Dyda, Federico Garcia, Rolf Kaiser, Sukran Köse, Henrik Krarup, Ivana Lazarevic, Maja M. Lunar, Sarah Maylin, Valeria Micheli, Orna Mor, Simona Paraschiv, Dimitros Paraskevis, Mario Poljak, Elisabeth Puchhammer-Stöckl, François Simon, Maja Stanojevic, Kathrine Stene-Johansen, Nijaz Tihic, Pascale Trimoulet, Jens Verheyen, Adriana Vince, Snjezana Zidovec Lepej, Nina Weis, Tülay Yalcinkaya, Charles A. B. Boucher, Annemarie M. J. Wensing, Carlo F. Perno, Valentina Svicher BMC Infectious Diseases, 2018
